-
2024-511096-15-00
5
2014-08-01
Breast Cancer
-
2024-512413-40-00
4
2013-03-08
Chronic myeloproliferative neoplasm
-
2025-521243-20-00
4
2025-10-23
Acromegaly
-
2024-516916-93-00
3
2025-09-08
This study will be a Phase 1b, global, multicenter, open-label, 2-part
-
2023-505840-20-00
9
2024-08-16
B-Cell Acute Lymphoblastic Leukaemia
-
2023-508730-34-00
9
2024-07-10
Non-small cell lung cancer (NSCLC):
- Locally advanced NSCLC where par
-
2024-515152-20-00
4
2023-03-02
Stage III and high-risk stage II resected colon cancer patients.
-
2023-506136-32-00
9
2020-10-12
Relapsed or Refractory B cell Precursor Acute Lymphoblastic Leukemia (
-
2025-521480-12-00
1
2025-10-22
Advanced solid tumors, Breast Cancer
-
2024-516699-14-00
7
2025-04-23
Non Small Cell Lung Cancer
Colorectal Cancer
Pancreatic Ductal Adenoca
-
2023-507865-24-00
5
2025-03-28
Advanced (unresectable/metastatic) melanoma
-
2024-511350-41-00
9
2025-03-13
Relapsed/Refractory Tumors
-
2024-514562-40-00
4
2025-03-13
Hidradenitis suppurativa (HS)
-
2024-513121-22-00
4
2025-02-04
Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
-
2023-505801-17-00
2
2025-01-15
Haemophilia A
-
2024-514559-13-00
10
2024-11-26
Focal Epilepsy
-
2024-512848-30-00
4
2024-11-12
HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE BREAST CANCER
-
2023-508812-45-00
10
2024-11-11
Idiopathic Generalized Epilepsy with Generalized Tonic-clonic Seizures
-
2023-504964-41-00
7
2024-11-06
Idiopathic pulmonary fibrosis
-
2023-509197-35-00
5
2024-10-17
Thyroid Eye Disease (TED)
-
2024-511360-87-00
5
2024-10-02
hidradenitis suppurativa (HS)
-
2023-509371-16-00
4
2024-09-25
Idiopathic Pulmonary Fibrosis
-
2024-511225-64-00
4
2024-09-18
Alopecia areata
-
2023-505797-15-00
5
2024-09-13
SYMPTOMATIC NON-OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY